Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients

Inclusion Criteria: * Renal transplant recipients at least 12 months post-transplantation aged ≥ 18 years. * Maintenance treatment with mycophenolate mofetil (in combination with tacrolimus with or without corticosteroids). * Stable dose of mycophenolate mofetil (≥ 500 mg twice daily) with no changes in immunosuppressive regimen for at least 6 weeks prior to the start of the study. * Stable renal graft function for at least 3 months. * Female patients must be either post-menopausal for ≥ 1 year, be surgically sterilized or a negative pregnancy test will be required immediately prior to study entry and such patients must continue to use effective contraception. * Willingness to undergo the study-related procedures. * Ability to comprehend and willingness to sign informed consent form. Exclusion Criteria: * History of allergy to mycophenolate mofetil, mycophenolic acid or any of the ingredients. * Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any organ other than kidney. * Rejection within the past 6 months prior to the start of the study. * Severe clinically relevant co-existing disease. * History of cancer other than skin cancer that has been cured. * History of serious clinically relevant digestive system disease during the last 12 months prior to start of the study. * Known or suspected hereditary deficiency of hypoxanthine-guanine-phosphoribosyltransferase (e.g., Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome). * Known or suspected liver impairment. * Clinically significant thrombocytopenia, anaemia, leukopenia, or neutropenia * Clinically significant laboratory and/or physical changes during the last 2 months prior to the start of the study. * Use of azathioprine, cholestyramine, sevelamer, or probenecid within 2 weeks prior to the first administration of study medication. * Change in concomitant medication during the 6 weeks prior to start of the study. * Use of any drug, prescribed or over-the-counter, (except stable concomitant medication) within 2 weeks prior to the first administration of study medication. * Planned or expected requirement for the use of live attenuated vaccines during the study. * Positive testing for HIV, Hepatitis B and C. * Clinical symptoms or laboratory evidence of cytomegalovirus infection in the last 6 month. * Pregnant or breast-feeding women. * Women of childbearing potential unable or unwilling to practice effective contraceptive measures for the duration of the study and for 6 weeks after the end of the study. * History of known or suspected alcohol or drug abuse. * Any other condition of the patient that, in the opinion of the investigator may compromise evaluation of the study treatment or may jeopardize patient's compliance or adherence to protocol requirements. * Previous enrollment in this study or participation in any other drug investigational trial within the past 6 weeks prior to enrollment.